Here’s Why Sanofi SA (ADR) (SNY) Is an Attractive Investment Opportunity

French pharmaceutical giant Sanofi SA (ADR) (NYSE:SNY)’s shares have gained about 20% over the past six months. The company has a diversified business model, spanning over various medical industries, including oncology, diabetes, heart diseases and nervous system disorders. The company posted better-than-expected first quarter results a few weeks ago. However, the company’s management warned investors that the diabetes division would decline in 2017.

Sanofi SA (ADR) (NYSE:SNY)’s Multiple Sclerosis franchise revenue was in-line with estimates. The company’s eczema drug Dupixent is getting a massive popularity. Dupixent is expected to get an approval in the EU very soon.

Sanofi SA (ADR) (NYSE:SNY) Chairman Serge Weinberg recently shot down all the rumors regarding Sanofi’s possible merger. Mr. Weinberg said that Sanofi SA (ADR) (NYSE:SNY) has a stable and satisfactory business of its own, and it doesn’t need any M&A.

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.